|
|
Post by robbmo on Jun 20, 2018 15:17:48 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-host-institutional-investor-and-analyst-meetingMannKind to Host Institutional Investor and Analyst Meeting Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes MannKind’s Chief Medical Officer Presenting New Afrezza® Data Released at American Diabetes Association’s 78th Scientific Sessions WESTLAKE VILLAGE, Calif., June 20, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it will host an invitation-only luncheon at Lotte New York Palace on Wednesday, June 27, 2018 for institutional investors and analysts, also accessible by live webcast (details below). This event will feature leading endocrinologist, Steven V. Edelman, MD, University of California - San Diego, who will discuss the current and novel approaches to treatment and management of diabetes in Type 1 and Type 2 patients. Michael Castagna, Chief Executive Officer of MannKind Corporation, will provide a corporate overview followed by MannKind’s Chief Medical Officer, David Kendall, presenting the latest Afrezza data released at the American Diabetes Association’s 78th Scientific Sessions held June 22-26, 2018. Dr. Edelman and MannKind’s management team will be available to answer questions at the conclusion of the event. Dr. Edelman is a Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California at San Diego (UCSD) and the Veterans Affairs (VA) Healthcare System of San Diego and the Director of the Diabetes Care Clinic, VA Medical Center. Dr. Edelman has strong interests in education and patient advocacy. He is the founder and director of Taking Control of Your Diabetes (TCOYD), a not-for-profit organization with the goal of teaching and motivating patients in diabetes self-care. Dr. Edelman was recently named in US News and World Report amongst the top 1% of endocrinologists in the United States.
|
|
|
|
Post by cjm18 on Jun 20, 2018 15:22:26 GMT -5
How many upgrades to the stock after this meeting?
|
|
|
|
Post by kc on Jun 20, 2018 15:22:57 GMT -5
Nice that they engaged Dr. Edelman very credible user. An expert in diabetes.
Kaboom!
|
|
|
|
Post by mannmade on Jun 20, 2018 15:38:14 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively...
Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage?
|
|
|
|
Post by golfeveryday on Jun 20, 2018 15:55:55 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively... Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage? I imagine this meeting is basically saying to them ‘hey, we now have the head to head data to support Afrezza growth and a new product in TrepT that will likely garner a partner, so now is your chance to get in on the ground floor.’ |
|
|
|
Post by buyitonsale on Jun 20, 2018 17:07:38 GMT -5
I agree... the $1st floor is always a ground floor  |
|
|
|
Post by peppy on Jun 20, 2018 17:18:16 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively... Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage? I imagine this meeting is basically saying to them ‘hey, we now have the head to head data to support Afrezza growth and a new product in TrepT that will likely garner a partner, so now is your chance to get in on the ground floor.’ My interpretation is the STAT Study. to be presented sat June 23 at ADA in an oral presentation. will host an invitation-only luncheon at Lotte New York Palace on Wednesday, June 27, 2018 for institutional investors and analysts, also accessible by live webcast (details below). This event will feature leading endocrinologist, Steven V. Edelman, MD, University of California - San Diego, who will discuss the current and novel approaches to treatment and management of diabetes in Type 1 and Type 2 patients.
Michael Castagna, Chief Executive Officer of MannKind Corporation, will provide a corporate overview followed by MannKind’s Chief Medical Officer, David Kendall, presenting the latest Afrezza data released at the American Diabetes Association’s 78th Scientific Sessions held June 22-26, 2018. Dr. Edelman and MannKind’s management team will be available to answer questions at the conclusion of the event. |
|
|
|
Post by mnkdfann on Jun 20, 2018 17:27:52 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively... Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage? IDK, but I suspect not. If they were at that point, they wouldn't need to offer a free lunch to attract interest. Also, I have a couple of relatives working at two different big banks in the states, and they are far too busy for this sort of thing. They deal with companies they are interested in one on one, not at a cattle call. And I wasn't aware that Wainwright or Maxim had discontinued coverage. Are you sure? Didn't Wainwright just issue coverage on Mannkind a few days ago? Interestingly, the Lotte New York Palace Hotel was formerly known as The Helmsley Palace Hotel. That name Helmsley keeps popping up today, in connection with Mannkind. |
|
|
|
Post by golfeveryday on Jun 20, 2018 17:27:53 GMT -5
I imagine this meeting is basically saying to them ‘hey, we now have the head to head data to support Afrezza growth and a new product in TrepT that will likely garner a partner, so now is your chance to get in on the ground floor.’ My interpretation is the STAT Study. to be presented sat June 23 at ADA in an oral presentation. will host an invitation-only luncheon at Lotte New York Palace on Wednesday, June 27, 2018 for institutional investors and analysts, also accessible by live webcast (details below). This event will feature leading endocrinologist, Steven V. Edelman, MD, University of California - San Diego, who will discuss the current and novel approaches to treatment and management of diabetes in Type 1 and Type 2 patients.
Michael Castagna, Chief Executive Officer of MannKind Corporation, will provide a corporate overview followed by MannKind’s Chief Medical Officer, David Kendall, presenting the latest Afrezza data released at the American Diabetes Association’s 78th Scientific Sessions held June 22-26, 2018. Dr. Edelman and MannKind’s management team will be available to answer questions at the conclusion of the event. yeah, STAT is head to head against Aspart/Novolog |
|
|
|
Post by kc on Jun 20, 2018 17:58:26 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively... Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage? Don't forget Aegis investments ......I am issuing you a YELLOW CARD.......
|
|
|
|
Post by brotherm1 on Jun 20, 2018 18:04:04 GMT -5
It’s by invitation only. Is that common?
|
|
|
|
Post by kc on Jun 20, 2018 18:12:51 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively... Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage? Interestingly, the Lotte New York Palace Hotel was formerly known as The Helmsley Palace Hotel. That name Helmsley keeps popping up today, in connection with Mannkind.Yes good point on Helmsley.....The Helmsley Charitable Foundation is a big supporter of Diabetes research. helmsleytrust.org/programs/health-type-1-diabetes
In the case of holding it at the Lotte Hotel that is probably just a coincidence.
I do believe at sometime in the past that I heard of a connection to Helmsley foundation and MannKind.
|
|
|
|
Post by tingtongtung on Jun 20, 2018 18:16:13 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively... Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage? Don't forget Aegis investments ......I am issuing you a YELLOW CARD.......
I almost forgot about those yellow cards.. Every single day with MNKD is crazy! |
|
|
|
Post by traderdennis on Jun 20, 2018 18:35:59 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively... Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage? Can you say dilution? Can you say additional warrants? it is doubtful the balance sheet is cleared up enough to get any kind of positive financing. |
|
|
|
Post by mannmade on Jun 20, 2018 19:49:26 GMT -5
I suspect this is why wainwright and maxim have downgraded us and discontinued coverage respectively... Could it be we have cleared up enough debt and now have a very credible CMO and are now able to attract Tier 1, 2 or 3 banks to finance us moving forward and possibly regain some analyst coverage? IDK, but I suspect not. If they were at that point, they wouldn't need to offer a free lunch to attract interest. Also, I have a couple of relatives working at two different big banks in the states, and they are far too busy for this sort of thing. They deal with companies they are interested in one on one, not at a cattle call. And I wasn't aware that Wainwright or Maxim had discontinued coverage. Are you sure? Didn't Wainwright just issue coverage on Mannkind a few days ago? Interestingly, the Lotte New York Palace Hotel was formerly known as The Helmsley Palace Hotel. That name Helmsley keeps popping up today, in connection with Mannkind. I could be wrong but I recall seeing an article that said Maxim had stopped covering Mnkd and i interpreted the recent downgrade from Wainwright as others did that we had moved on, so my hope (not a strategy) was that we might attract a larger bank using the results from the stat study as the basis. Guess we will find out soon. |
|
